Emmaus Life Sciences, Inc. to Present Results of Phase 3 Study of EndariTM (L-glutamine oral powder) at 59th American Society of Hematology Annual Meeting Nov 28, 2017 9:00am EST
The U.S. Food & Drug Administration Approves Endari™ (L-glutamine oral powder), the First and Only Treatment for Sickle Cell Disease in Pediatric Patients and First in Nearly 20 Years for Adults Jul 07, 2017 3:57pm EDT
FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell Disease May 24, 2017 5:43pm EDT
Emmaus Life Sciences Inc. Announces FDA Advisory Committee Meeting for Endari™ for Sickle Cell Disease Apr 18, 2017 8:00am EDT
Emmaus Life Sciences, Inc. to Present at Los Angeles Biomedical Research Institute's (LA BioMed) Innovation Showcase Mar 08, 2017 8:00am EST
Emmaus Life Sciences, Inc. Receives Notice of Allowance for Japanese Patent for use of L-glutamine in Treatment of Diabetes Feb 07, 2017 8:00am EST
Emmaus Life Sciences, Inc. Receives Notice of Allowance for U.S. Patent for use of L-glutamine in Treatment of Diverticulosis Feb 01, 2017 8:00am EST
Yutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology Corporation Jan 25, 2017 8:00am EST
Emmaus Life Sciences, Inc. Enters into Collaborative Agreement with Generex Biotechnology Corporation Jan 24, 2017 8:00am EST
Emmaus Life Sciences, Inc. Receives Japanese Patent for use of L-glutamine in Treatment of Diverticulosis Dec 13, 2016 8:00am EST
